Sternon J
Chargé de Missions Hôpital Erasme et C.U.M.G.-U.L.B.
Rev Med Brux. 2001 Apr;22(2):100-5.
The coxibs, specific anti-Cox-2, represent an interesting evolution for the treatment of patients suffering from rheumatic conditions and presenting gastrointestinal ulcer risk. Anti-inflammatory effectiveness is comparable with the other NSAIDs, but the toxicity for the gastrointestinal mucosa is slightly lower. Contra-indications, extradigestive adverse affects and interactions are the same as for any other NSAIDs. Their risks and cost must be taken into account as such as the rheumatic condition of the patient. They may be prescribed to patients presenting a gastrointestinal risk and the relevant cost is reasonable. Pharmacovigilance survey at mid to long term is necessary.
昔布类药物，即特异性环氧化酶-2（Cox-2）抑制剂，是治疗患有风湿性疾病且有胃肠道溃疡风险患者的一种有趣的药物进展。其抗炎效果与其他非甾体抗炎药相当，但对胃肠道黏膜的毒性略低。禁忌证、消化道外不良反应及相互作用与其他任何非甾体抗炎药相同。必须考虑到它们的风险、成本以及患者的风湿性疾病状况。可将其处方给有胃肠道风险的患者，且相关成本合理。有必要进行中长期药物警戒调查。
